LONDON, 23 April 2018:

Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience”, “Arix” or the “Company”), a global life sciences company supporting medical innovation, today announces its annual results for the year ended 31 December 2017.

Highlights within the period

  • Successful IPO on the Main Market of the London Stock Exchange in February 2017, raising £112 million
  • Acquired direct interests in 8 new Arix Group Businesses, bringing the total portfolio to 13 Group Businesses
  • Strategic agreements signed with Takeda Ventures, Inc., and UCB Pharma S.A.
  • Led or participated in eight Group Business fundraisings:
    • Led a $65 million Series B investment round for Iterum Therapeutics
    • Led a $45 million Series B investment round for LogicBio Therapeutics
    • Led $30m Series F financing round for Atox Bio
    • Co-led a $45 million Series B investment round for Harpoon Therapeutics
    • Co-led a $29 million Series A financing for PreciThera
    • Co-led $30 million series C financing round for Aura Biosciences
    • Participated in a $20 million Series A investment round for Mitoconix Bio
    • Participated in $67m Series C financing round for Amplyx Pharmaceuticals
  • Encouraging progress in the development of existing Arix Group Businesses
    • Verona Pharma plc successfully listed on NASDAQ, raising c. $80 million
    • Autolus commenced three clinical trials in multiple myeloma, non-Hodgkin’s lymphoma and T cell lymphoma
    • Amplyx Pharmaceuticals released positive data from two Phase 1 and five non-clinical trials showing tolerability, safety and non-clinical efficacy
    • Revaluation uplifts from Autolus and Harpoon Therapeutics:
      • Autolus raised a further $80 million in a series C financing at a c. 50% uplift in valuation.
      • Harpoon Therapeutics signed a collaboration agreement with AbbVie to develop novel T-cell engager therapies, resulting in an increase in the value of Arix’s holding by approximately 25%
    • Period-end cash balance of £74.9 million

Highlights post-period end

  • Successful £87 million fundraise by the Company from new and existing investors
  • Strategic agreements signed by the Company with Fosun International Limited and Ipsen
  • Positive Phase 2 data announced by Verona Pharma in COPD

“2017 was a transformational year for Arix, as we delivered on the objectives stated at the time of our IPO in February. The IPO brought £112 million of new capital, which enabled us to identify and support eight new innovative life science companies, bringing our total at the end of the year to 13 Group Businesses. Since then we have raised a further £87 million and our pipeline of opportunities continues to grow, supported by our broad international network. We are also fortunate to have secured strategic partnerships with leading global pharmaceutical companies Takeda, UCB, Fosun and Ipsen. “Looking ahead, we anticipate multiple clinical and financing catalysts in our Group Businesses and we are also planning to build interests in more exciting young companies. We believe our approach has the potential to generate significant value for patients and for investors, and we are grateful to our shareholders for supporting us in this mission.”

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience


Joe Anderson, Chief Executive Officer, and James Rawlingson, Chief Financial Officer, will host a lunch briefing and call for analysts at 12:00 BST at Stifel, 150 Cheapside, London, EC2V 6ET. Details of the call will be available on request. The call will be recorded and a replay will be available on Arix’s website.